At what enterprise value was CAMBREX CORPORATION acquired in 2019?

During the acquisition of CAMBREX CORPORATION by PERMIRA in 2019, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CAMBREX CORPORATION when it was acquired by PERMIRA?

The estimated EV/EBITDA multiple for CAMBREX CORPORATION is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was CAMBREX CORPORATION acquired by PERMIRA?

CAMBREX CORPORATION was acquired by PERMIRA in 2019.

What was the revenue of CAMBREX CORPORATION at the time of the deal?

The revenue of CAMBREX CORPORATION at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of CAMBREX CORPORATION during the acquisition?

CAMBREX CORPORATION's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CAMBREX CORPORATION acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CAMBREX CORPORATION deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.permira.com/news-and-insights/announcements/cambrex-to-be-acquired-by-the-permira-funds-for-6000-per-share-in-cash

← DATABASE

Home Database Healthcare & PharmaCAMBREX CORPORATION

08/2019

CAMBREX CORPORATION acquired by PERMIRA

UNITED STATES Life Sciences / Pharma & Biotech / CDMO EV 1b - 4b EUR

Context

Permira, the global private equity firm, successfully completed the acquisition of Cambrex Corporation, a premier small molecule CDMO, in a take-private transaction that signaled a major consolidation move in the pharmaceutical services sector. The transaction was structured as a merger whereby shareholders received $60.00 in cash per share, representing a significant premium of 47.1% over the undisturbed share price. The deal allowed Cambrex to delist from the New York Stock Exchange and transition into a private entity, providing the management team with the long-term capital and operational flexibility required to further integrate its acquisitions and invest in global capacity expansion. Permira's investment thesis focused on capitalizing on the increasing trend of pharmaceutical companies outsourcing complex chemical manufacturing and analytical testing.

CAMBREX CORPORATION, which reported an EBITDA margin of LOGIN in 2018, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Cambrex is a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle. Specialized in the small molecule space, the company supports pharmaceutical clients from pre-clinical stages through to commercial manufacturing. It operates 13 locations across North America and Europe with over 2,000 employees.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2019	DENTRESSANGLE	MARLE GROUP	FRANCE	Life Sciences	Dentressangle has entered into exclusive negotiations to acquire a majority stake in Marle Group from IK Investment Partners on a preemptive basis, successfully securing the asset outside of a traditional, highly competitive auction process
09/2019	SAGARD	STERIMED	FRANCE	Life Sciences	Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins
07/2019	PERMIRA	QUOTIENT SCIENCES	UNITED KINGDOM	Life Sciences	Permira acquired a majority stake in Quotient Sciences from GHO Capital, which had owned the business since 2015. Under GHO's four-year ownership, the company underwent a major transformation, expanding its service offering into commercial manufacturing and establishing a significant presence in the United States through strategic investments and acquisitions
07/2019	3I	IONISOS	FRANCE	Life Sciences	Ionisos, a leading European specialist in cold sterilization services, has entered its fifth LBO cycle following its acquisition by 3i Infrastructure. The London-listed investor is deploying �220 million to acquire up to 100% of the company's equity from Ardian Expansion, which had held the asset since 2016
05/2019	ARDIAN	SINTETICA	SWITZERLAND	Life Sciences	Ardian acquired a majority stake in Sintetica from the majority shareholder Daphne and the owner family. The transaction was structured as a partnership, with the existing shareholders and management team reinvesting via a significant minority stake to maintain continuity
04/2019	EURAZEO	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Life Sciences	Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market
04/2019	ICG / MERIEUX EQUITY PARTNERS	DOC GENERICI	ITALY	Life Sciences	ICG acquired 100% of DOC Generici from CVC Capital Partners, marking the company's third private equity cycle. Merieux Equity Partners joined as a strategic co-investor to leverage its industrial expertise in life sciences
12/2018	MERCK & CO.	ANTELLIQ	FRANCE	Life Sciences	The global life sciences leader has finalized the acquisition of 100% of the share capital of the target from a prominent European private equity firm. This strategic transaction represents a definitive move to incorporate advanced digital capabilities into the group’s specialized animal health division, targeting the high-growth segment of animal intelligence and monitoring
11/2018	ARDIAN	NEOPHARMED GENTILI	ITALY	Life Sciences	Ardian acquired a majority stake in Neopharmed Gentili from its founding parent company, Mediolanum Farmaceutici. The Del Bono family, founders of Mediolanum, retained a 20% minority stake in the business to ensure operational and clinical continuity
10/2018	BRIDGEPOINT	HTL BIOTECHNOLOGY	FRANCE	Life Sciences	Bridgepoint has acquired a majority stake in HTL, the specialized producer of hyaluronic acid, in a secondary LBO transaction from Naxicap Partners. This operation follows a period of rapid development under the previous sponsor, which had orchestrated a management buy-in (MBI) only eighteen months prior

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CAMBREX CORPORATION by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: permira